Orphan Drug Designation Granted to SK Biopharmaceuticals’ Carisbamate for the Management of Infantile Spasms

April 20, 2012
SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the FDA for carisbamate for the management of patients with infantile spasms, a form of epilepsy associated with increased risk of death or mental retardation.
Genetic Engineering & Biotechnology News